Establishing a novel single-copy primer-internal intron-spanning PCR (spiPCR) procedure for the direct detection of gene doping

Exercise Immunology Review

Volumn 14, Issue , 2008, Pages 73-85

  Beiter, Thomas ^a   Zimmermann, Martina ^a   Fragasso, Annunziata ^a   Armeanu, Sorin ^a   Lauer, Ulrich M ^a   Bitzer, Michael ^a   Su, Hua ^b,c   Young, William L ^b   Niess, Andreas M ^a   Simon, Perikles ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Direct detection; Gene doping; Gene therapy; Gene transfer; SpiPCR; Transgenic DNA

Indexed keywords

DNA; ERYTHROPOIETIN; VASCULOTROPIN D;

ARTICLE; BLOOD; DOPING; ETHICS; GENE THERAPY; GENETICS; HUMAN; METABOLISM; METHODOLOGY; POLYMERASE CHAIN REACTION; TRANSGENE;

DNA; DOPING IN SPORTS; ERYTHROPOIETIN; GENE THERAPY; HUMANS; POLYMERASE CHAIN REACTION; TRANSGENES; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 62849115532     PISSN: 10775552     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Komor M, Guller S, Baldus CD, de VS, Hoelzer D, Ottmann OG, et al. Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiation. Stem Cells 2005 Sep;23(8):1154-69. (Pubitemid 41377731)
2. Kawai M, Namba N, Mushiake S, Etani Y, Nishimura R, Makishima M, et al. Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the Stat5A/5B-PPARgamma pathway. J Mol Endocrinol 2007 Feb;38(1-2):19-34. (Pubitemid 46351590)
3. Svensson J, Tivesten A, Sjogren K, Isaksson O, Bergstrom G, Mohan S, et al. Liver-derived IGF-I regulates kidney size, sodium reabsorption, and renal IGF-II expression. J Endocrinol 2007 Jun;193(3):359-66. (Pubitemid 47033745)
4. Simon P, Fehrenbach E, Niess AM. Regulation of immediate early gene expression by exercise: short cuts for the adaptation of immune function. Exerc Immunol Rev 2006;12:112-31.
5. Labrie F, Luu-The V, Calvo E, Martel C, Cloutier J, Gauthier S, et al. Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. J Endocrinol 2005 Feb;184(2):427-33. (Pubitemid 40347232)
6. Sweeney HL. Gene doping. Sci Am 2004 Jul;291(1):62-9.
7. Adam D. Gene therapy may be up to speed for cheats at 2008 Olympics. Nature 2001 Dec 6;414(6864):569-70.
8. Baoutina A, Alexander IE, Rasko JE, Emslie KR. Developing strategies for detection of gene doping. J Gene Med 2008 Jan;10(1):3-20.
9. Harridge SD, Velloso CP. Gene doping. Essays Biochem 2008;44:125-38.
10. Minunni M, Scarano S, Mascini M. Affinity-based biosensors as promising tools for gene doping detection. Trends Biotechnol 2008 May;26(5):236-43.
11. Baoutina A, Alexander IE, Rasko JE, Emslie KR. Potential use of gene transfer in athletic performance enhancement. Mol Ther 2007 Oct;15(10):1751-66. (Pubitemid 47434181)
12. Striegel H, Simon P. [Doping. High-tech cheating in sport]. Internist (Berl) 2007 Jul;48(7):737-42.
13. Haisma HJ, de HO. Gene doping. Int J Sports Med 2006 Apr;27(4):257-66.
14. Schneider AJ, Friedmann T. Gene doping in sports: the science and ethics of genetically modified athletes. Adv Genet 2006;51:1-110.
15. Unal M, Ozer UD. Gene doping in sports. Sports Med 2004;34(6):357-62. (Pubitemid 38803098)
16. McCrory P. Super athletes or gene cheats? Br J Sports Med 2003 Jun;37(3):192-3. (Pubitemid 36713703)
17. Diamanti-Kandarakis E, Konstantinopoulos PA, Papailiou J, Kandarakis SA, Andreopoulos A, Sykiotis GP. Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. Sports Med 2005;35(10):831-40. (Pubitemid 41464509)
18. Wells DJ. Gene doping: the hype and the reality. Br J Pharmacol 2008 Jun;154(3):623-31. (Pubitemid 351744949)
19. Murray TH. Reflections on the ethics of genetic enhancement. Genet Med 2002 Nov;4(6 Suppl):27S-32S. (Pubitemid 44133566)
20. Bamford KB, Wood S, Shaw RJ. Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS Teaching Hospital Trust. QJM 2005 Feb;98(2):75-86. (Pubitemid 40277564)
21. Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, et al. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 2005 Jan;16(1):17-25. (Pubitemid 40250328)
22. Gonin P, Buchholz CJ, Pallardy M, Mezzina M. Gene therapy bio-safety: scientific and regulatory issues. Gene Ther 2005 Oct;12 Suppl 1:S146-S152. (Pubitemid 41541764)
23. Horn P, Kalz A, Lim CL, Pyne D, Saunders P, Mackinnon L, et al. Exercise-recruited NK cells display exercise-associated eHSP-70. Exerc Immunol Rev 2007;13:100-11.
24. Nagatomi R. The implication of alterations in leukocyte subset counts on immune function. Exerc Immunol Rev 2006;12:54-71.
25. Gleeson M, McFarlin B, Flynn M. Exercise and Toll-like receptors. Exerc Immunol Rev 2006;12:34-53.
26. Peake JM, Nosaka K, Muthalib M, Suzuki K. Systemic inflammatory responses to maximal versus submaximal lengthening contractions of the elbow flexors. Exerc Immunol Rev 2006;12:72-85.
27. Shing CM, Ogawa K, Zhang X, Nagatomi R, Peake JM, Suzuki K, et al. Reduction in resting plasma granulysin as a marker of increased training load. Exerc Immunol Rev 2007;13:89-99.
28. Lasne F, Martin L, de Ceaurriz J, Larcher T, Moullier P, Chenuaud P. "Genetic Doping"with erythropoietin cDNA in primate muscle is detectable. Mol Ther 2004 Sep;10(3):409-10. (Pubitemid 39186104)
29. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res 2002 Jun;12(6):996-1006. (Pubitemid 34662293)
30. Wybranietz WA, Prinz F, Spiegel M, Schenk A, Bitzer M, Gregor M, et al. Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines. J Gene Med 1999 Jul;1(4):265-74. (Pubitemid 129631119)
31. Gonin P, Gaillard C. Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther 2004 Oct;11 Suppl 1:S98-S108. (Pubitemid 39359454)
32. Freytag SO, Khil M, Stricker H, Peabody J, Menon M, Peralta-Venturina M, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002 Sep 1;62(17):4968-76. (Pubitemid 34984421)
33. Favre D, Provost N, Blouin V, Blancho G, Cherel Y, Salvetti A, et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther 2001 Dec;4(6):559-66. (Pubitemid 34026871)
34. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006 Mar;12(3):342-7. (Pubitemid 43355084)
35. Powell JS, Ragni MV, White GC, Lusher JM, Hillman-Wiseman C, Moon TE, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003 Sep 15;102(6):2038-45. (Pubitemid 37122377)
36. Kruger K, Mooren FC. T cell homing and exercise. Exerc Immunol Rev 2007;13:37-54.